Flavoxine^™ is a new, all natural patented (U.S. Patent No. 6,987,125 and U.S. Patent No. 6,184,246) proprietary combination of two plant extracts that have been shown in animal studies to have cholesterol lowering properties and possibly other benefits for cardiovascular disorders. In a double-blind, placebo-controlled clinical trial with 80 subjects, Flavoxine^™ significantly (p<0.001) lowered weight and BMI by 5% in the overweight subjects. Lipid lowering was seen in both groups in all measurements. Flavoxine^™ significantly reduced circulating LDL-cholesterol by 49% in 8 weeks in the overweight group (p<0.001) and by17% in the normal weight group (p<0.01). Flavoxine^™ significantly increased HDL-cholesterol in the overweight subjects by 12% after 8 weeks (p<0.05). A statistically significant increase (p<0.05) was also shown in the normal weight subjects.

C-reactive protein, an indicator of inflammation that is now considered to be a positive risk factor for coronary artery disease, was significantly (p<0.001) reduced by Flavoxine^™ in the overweight group by 48% at 8 weeks and in the normal weight group by 44% (p<0.001). Flavoxine^™ after 8 weeks also significantly (p<0.05) reduced the concentration of triglycerides by 18% in the overweight group and by 15% (p<0.001) in the normal weight group. Blood pressure was significantly lowered in both Flavoxine^™ groups at 8 weeks. The overweight group lowered their systolic blood pressure by 6% (p<0.05) and their diastolic blood pressure by 13% (p<0.001), while the normal weight group dropped their diastolic blood pressure by 12% (p<0.01). Flavoxine^™ is clearly the leading natural product for maintaining heart health!